Nijenhuis VJ, Brouwer J, Delewi R, et al. - Researchers assessed the roles of anticoagulation alone or with an antiplatelet agent following transcatheter aortic-valve implantation (TAVI) in this randomized trial. Patients receiving TAVI who were on oral anticoagulation for appropriate indications were included. The participants were allocated prior to TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months. All bleeding and non–procedure-associated bleeding over a span of 12 months were regarded as two primary outcomes. Over a span of 1 month or 1 year, lower incidence of serious bleeding was reported in relation to oral anticoagulation alone vs with oral anticoagulation plus clopidogrel among patients undergoing TAVI who were taking oral anticoagulation.